

# SCIENTIFIC REPORTS



OPEN

## Characteristics, chemical compositions and biological activities of propolis from Al-Bahah, Saudi Arabia

Received: 17 October 2016  
Accepted: 16 December 2016  
Published: 06 February 2017

Yasser A. Elnakady<sup>1</sup>, Ahmed I. Rushdi<sup>2,3</sup>, Raimo Franke<sup>4</sup>, Nael Abutaha<sup>5</sup>, Hossam Ebaid<sup>1</sup>,  
Mohannad Baabbad<sup>5</sup>, Mohamed O. M. Omar<sup>6</sup> & Ahmad A. Al Ghamdi<sup>6</sup>

Propolis has been used to treat several diseases since ancient times, and is an important source of bioactive natural compounds and drug derivatives. These properties have kept the interest of investigators around the world, leading to the investigation of the chemical and biological properties and application of propolis. In this report, the chemical constituents that are responsible for the anticancer activities of propolis were analyzed. The propolis was sourced from Al-Baha in the southern part of the Kingdom of Saudi Arabia. Standard protocols for chemical fractionation and bioactivity-guided chemical analysis were used to identify the bio-active ethyl acetate fraction. The extraction was performed in methanol and then analyzed by gas chromatography-mass spectrometry (GC-MS). The major compounds are triterpenoids, with a relative concentration of 74.0%; steroids, with a relative concentration of 9.8%; and diterpenoids, with a relative concentration of 7.9%. The biological activity was characterized using different approaches and cell-based assays. Propolis was found to inhibit the proliferation of cancer cells in a concentration-dependent manner through apoptosis. Immunofluorescence staining with anti- $\alpha$ -tubulin antibodies and cell cycle analysis indicated that tubulin and/or microtubules are the cellular targets of the L-acetate fraction. This study demonstrates the importance of Saudi propolis as anti-cancer drug candidates.

More than twenty percent of the world's population is suffering from malignant diseases. According to the American Cancer Society, 14.1 million cancer cases were diagnosed in 2012 worldwide, and more than half of these cases occurred in economically developing countries<sup>1</sup>. Additionally, approximately 8.2 million cancer patients around the world lost their lives in 2012. Furthermore, by 2030, the number of cancer patients is expected to increase to 21.7 million<sup>1</sup>. The development of an effective cancer therapy remains one of the greatest challenges for the scientific community, with little advancement in the overall cancer survival landscape during the last two decades. The administration of different therapeutic agents for cancer treatment (which also includes those from natural sources such as Taxol or vinca alkaloids) are known to produce a variety of side effects<sup>2-5</sup>. Moreover, extensive radiotherapy usually leads to other illnesses in patients, such as hematopoietic syndrome, mucositis, and other afflictions<sup>6-9</sup>. In recent years, efforts have been made to identify naturally occurring agents that could prevent cancer development without (or with minimal) side effects.

As a traditional alternative medicine approach, honeybees and/or honeybee products (e.g., venom and propolis) have been used to relieve pain and to treat inflammation since ancient times<sup>10</sup>. A survey of the literature indicates a recent revival of interest in exploring the medical properties of honeybee venom and propolis<sup>11</sup>. Different research groups around the world have reported the antibacterial, antifungal, cytostatic, wound healing, antitumor and anti-inflammatory properties of honeybee products<sup>12-24</sup>. Propolis contains more than 300 components,

<sup>1</sup>College of Sciences, Department of Zoology, King Saud University, Riyadh 11451, Saudi Arabia. <sup>2</sup>Chair of Green Energy Research, College of Food and Agriculture Sciences, King Saud University, P. O. Box 2460, Riyadh 11451, Saudi Arabia. <sup>3</sup>ETAL Consulting and Service, 2951 SE Midvale Drive, Corvallis, OR 97333, USA. <sup>4</sup>Department of Chemical Biology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany. <sup>5</sup>Chair of Bio-product, College of Science, King Saud University, Riyadh 11451, Saudi Arabia. <sup>6</sup>Chair of Engineering Abdullah Baqshan for Bee Research, College of Food and Agriculture Sciences, King Saud University, Riyadh, Saudi Arabia. Correspondence and requests for materials should be addressed to Y.A.E. (email: yelnakady@ksu.edu.sa)

| Cell line | ATCC-       | Disease                  | IC <sub>50</sub> -Methanol Extract (µg/ml) | IC <sub>50</sub> -L-acetate fraction (µg/ml) |
|-----------|-------------|--------------------------|--|--|
| Jurkat    | TIB152      | Acute T leukemia         | 70   | 3.2  |
| A549      | CRM-CCL-185 | Lung carcinoma           | 37   | 1.8  |
| HepG2     | HB-8065     | Hepatocellular carcinoma | 3  | 6.3  |
| SW756     | CRL-10302   | Squamous carcinoma       | 200  | 2.8  |

**Table 1.** IC<sub>50</sub>-Values for a crude methanol extract of propolis and the L-acetate fraction in four different cell lines as measured by MTT Assay.

including phenolic aldehydes, polyphenols, amino acids, steroids, and inorganic compounds. However, the plant origin and the collection region can substantially affect the chemical composition of propolis<sup>25–34</sup>. The pharmacological potential of propolis has been very well investigated and reported in the literature, as evidenced by the large number of related reports<sup>25–39</sup>. *In vivo* studies have also been performed in which the administration of propolis to mice or humans does not seem to lead to any side effects<sup>40–43</sup>.


Propolis is a glue material that is collected by honeybees from plants and then used for sealing cracks in hives and protecting the bees from bacterial and fungal infections<sup>44,45</sup>. Ancient Egyptians, Romans and Greeks used propolis in the past as a medicine for curing some diseases<sup>46</sup>. The curative properties are correlated with the bio-active chemicals that are present in propolis and have sparked an interest in further explorations. An important aspect of the properties/characteristics could be related to geographical location, because the plant sources and collecting season for honeybees are different, adding another important factor to the diversity of the propolis chemical constituents and thereby adding to the biological activities<sup>47</sup>. Generally, the known major components of propolis are aromatic acids, flavonoids, diterpenoid acids, phenolic compounds and triterpenoids. Since honeybees visit the flowers of different plants, these plants are the major source of organic compounds in propolis during propolis formation by honeybee secretion and metabolism. The compositional breakdown of propolis is unsurprisingly 30% wax, 50% resin and vegetable balsam, 5% pollen, 10% essential and aromatic oils and 5% other substances<sup>48–59</sup>. The reported compositions mostly come from Europe and Latin America<sup>60–74</sup>, whereas there are few reports on the propolis of Saudi Arabia<sup>47,75</sup>. Saudi Arabia makes up the major part of the Arabian Peninsula and has dry climatic and physiographic conditions, except in the eastern and southern regions, where different species of flowering plants are found<sup>75,76</sup>. Honeybees produce a considerable amount of propolis in the Al-Bahah region, where many beekeepers focus only on honey production. This survey indicates a need to investigate the effects of these dry climates on the characteristics of propolis from the Arabian Peninsula.

Therefore, in this study, propolis samples were collected from the southern region of the Kingdom of Saudi Arabia to investigate their chemical compositions and anti-proliferative activities and understand the effects of regional diversity and geographical locations relative to those of reported studies from other parts of the world.

## Results

**Effects of propolis extract on the proliferation of cancer cell lines.** Initially, the effects of propolis extracts were ascertained on the proliferation of four cancer cell lines that included Jurkat (T lymphocyte leukemia), HepG2 (human liver carcinoma), A549 (human lung carcinoma), and SW756 (squamous carcinoma) cell lines. Extracts from every 30 grams of propolis were obtained in two sets of 500 ml of methanol (95%). The resulting fractions were mixed and dried. This extraction yields 4.55 g of crude methanol extract (approximately 15.2% of the starting material). Two grams of the methanol crude extract were further purified using ethyl acetate and silica gel column chromatography as described in the methods section. This approach yielded 1.57 g of ethyl acetate fraction (L-acetate, L for local propolis, and acetate for ethyl acetate). The bio-activities of the two fractions were tested using an MTT assay. Table 1 shows a comparison between the anti-proliferation activities of methanol crude fractions versus that of the L-acetate fraction as measured in the MTT assay. The four cancer cell lines showed sensitivities to both fractions. However, three of the four tested cancer cell lines, namely the Jurkat, A549 and SW756 cells, exhibited great sensitivity to the ethyl acetate fraction of the propolis in comparison to its crude methanol extract. The measured IC<sub>50</sub> values ranged between 1.8 and 3.2 µg/ml. By contrast, the sensitivity of HepG2 to the L-acetate fraction was lower than that measured for the methanol crude extract, and the measured IC<sub>50</sub> values were 6.3 and 3 µg/ml, respectively.

**Impedance profiling of L-acetate fractions.** To obtain insight into the way in which L-acetate fraction inhibit the growth of the treated cells, we employed a modern chemical biology technique to test the effects of propolis extracts on the profiles of L-929 cells (mouse fibroblasts) by monitoring the impedance of the treated cells followed by cluster analysis with compounds with known mechanisms of action. The principle of the impedance profiling approach is that compounds with a similar mode of action induce similar time-dependent impedance curves. Thus, when the curve is induced by a compound (or extract) of interest, it is compared to the curves of the reference compounds whose mode of action is known, providing hints about the action of the new compound. The impedance curves of the L-acetate fraction were compared to those of a set of 27 compounds covering a broad activity spectrum. As shown in Fig. 1, the L-acetate fraction was found to cluster with tubulysin B<sup>77</sup>, griseofulvin<sup>78</sup>, and nocodazol<sup>79</sup>. The three compounds are known to bind to tubulin and interfere with microtubule function. In other words, the activity of the L-acetate fraction seems to interact with tubulin as the cellular target. This finding was supported by the immunofluorescence staining of PtK2 cells using anti- $\alpha$ -tubulin antibodies. As shown in Fig. 2, the treatment of PtK2 cells (potoroo kidney cells) with a 100 µg/ml L-acetate fraction induces the



**Figure 1.** Hierarchical cluster analysis of data from impedance curves obtained with L929 cells that were incubated with L-acetate fraction and as a set of reference compounds L-acetate fraction found in close proximity to tubulysin B, griseofulvin, and nocardazol. The three compounds are known to interact with tubulin as a cellular target.

de-polymerization of interphase microtubules as well as nuclei fragmentation (a hallmark of apoptosis). However, the de-polymerization effect of L-acetate was only observed after a long incubation time (24 hours).

Because the compounds that bind tubulin usually caused G<sub>2</sub>M cell cycle arrest in the treated cells<sup>80</sup>, we tested the effects of the L-acetate fraction on the cell cycle distribution of Jurkat cells. As shown in Fig. 3B, Jurkat cells were accumulated over the G<sub>2</sub>M-phase 24 hours after treatment with 100 µg/ml of L-acetate fraction in comparison to the control cells (Fig. 3A). We could also detect a substantial increase in the number of apoptotic cells.


Consequently, we tested the effect of the L-acetate fraction on the induction of apoptosis in Jurkat cells using AnnexinV-FITC/PI staining and flow cytometry. This staining was chosen on the basis of the observation that soon after initiating apoptosis, the cells translocate their membrane phosphatidylserine (PS) from the inner face of the plasma membrane to the cell surface. Once it reaches the cell surface, the PS can be detected easily by staining it with a fluorescent conjugate of Annexin V, a protein that has a high affinity for PS. As a result of apoptosis initiation, the membrane loses its integrity, leading to the diffusion of PI (Propidium Iodide) into the cells, and it binds to the DNA. Therefore, the staining of a cell with Annexin-V-FITC indicates that the cells are in an early apoptotic stage, and staining the cells (DNA) with PI indicates that the cell is in a late apoptotic or necrotic phase.

As shown in Fig. 4, the control sample (Fig. 4A) was treated only with methanol (-ve control), and it displayed more than 93% living, non-apoptotic cells (E3). After three hours of incubation with 100 µg/ml L-acetate, the cell distribution remained almost unchanged (Fig. 4B). However, after nine hours of incubation, the percentage of living cells was dramatically decreased (from 92.7 to 27.2), and we observed a huge increase in early-stage apoptotic cells (Fig. 4C). After 24 hours of incubation, we observed only 3.7% living cells and 52.2% early stage apoptotic cells, and 41% of the cell population was in the late apoptotic stage (Fig. 4D). These results clearly indicate that the L-acetate fraction of the Saudi propolis induces apoptosis in Jurkat cells.

**Effects of the L-Acetate Fraction on Rats (*Rattus norvegicus*).** We tested the effects of the L-acetate fraction on physiological and histological functions in male Wistar rats (*Rattus norvegicus*). The rats were divided into two groups, each of which contained ten rats. Group 1 served as the control and only received the vehicle. Group 2 received a daily intraperitoneal dose of 1 mg/kg body weight of the ethyl acetate fraction. The histological architecture of the renal tissues from both the control and treated rats were shown to be normal without any significant changes in either the glomeruli or convoluted tubules (Fig. 5A and B). The control hepatic tissues showed normal histological architecture. Unlike the control, a number of vacuolated hepatocytes and abnormally narrowed hepatic sinusoids were found in the sections that were taken from treated rats (Fig. 5C and D). Collagen deposits were found to surround the central veins, and none of these fibers appeared in the interlobular regions. Hepatic tissues from control and L-acetate-treated rats appeared to be similar when stained with reticulin stain (Fig. 5E and F).

According to an ANOVA analysis of variance, no significant changes were induced by the L-acetate fraction in the treated rats compared to the control non-treated rats in the concentrations of all the measured biochemical assays, namely, AST, ALT, cholesterol, HDL, protein, creatinine and glucose (Table 2).

**Chemical Constituents of the L-Acetate Fraction.** The major L-acetate fraction's relative concentrations of organic compounds are listed in Table 3, and the features of the GC-MS results for the propolis samples are shown in Fig. 6. The major extractable organic compound primarily included triterpenoids (74.0% of the total extract), steroids (9.8% of the total extract) and diterpenoids (7.9% of the total extract). The dominant compounds of the triterpenoids were α- and β-amyrin acetates (29.2% total extract), α- and β-lupeol acetates (14.9% total extract), α- and β-amyrins (8.7% total extract), oleana-9(11)-dien-3β-yl acetate (2.4% total extract), lupeol (1.9% total extract), taraxasterol (1.4% total extract), urs-9(11),12-dien-3-one (1.3% total extract), and moretenol (1.1% total extract). The primary steroid compounds included cycloartenol (3.2% total extract), lanosterol (2.8%




**Figure 2.** Effect of L-acetate fraction on the microtubules of PtK2 cells as shown by immunofluorescence technique using anti- $\alpha$ -tubulin antibodies (red). Nuclei stained with DAPI (blue). (A) Control Cell, (B), and (C) treated cells (100  $\mu$ g/ml, 24 h).

total extract), taraxasterol (1.4% total extract), lanostenyl acetate (1.3% total extract) and cycloartenyl acetate (1.1% total extract). The major diterpenoid compounds were primarily phenolics and included ferruginol (4.9% total extract), sugiol (1.3% total extract), totarol (1.0% total extract), hinokione (0.4% total extract), and hinokiol (0.3% total extract). No flavonoids were detected in the propolis from this region.


## Discussion

Many reports have described the biological activities of propolis samples that have been collected from different geographical regions of the world<sup>25,51,77–80</sup>. These properties include antimicrobial, antioxidant, anti-inflammatory, anti-viral and anticancer activities<sup>69,72,79,81–84</sup>. However, little is known about the biological activities of Saudi propolis, especially its effects on cancer cell lines. In this study, we investigated the anti-proliferative effect of an ethyl acetate fraction of local Saudi propolis (L-acetate fraction) against a number of cancer cell lines. In addition, we analyzed its chemical composition and its mechanism of action, and finally, we tested the side effects of this fraction in a rat model.

The major components of the L-acetate fraction were triterpenoids (74.0% of the total extract), steroids (9.8% of the total extract) and diterpenoids (7.9% of the total extract), which reflect the importance of Saudi propolis as a source of bio-active metabolites. Some of the components were detected as acetate salts and others were identified as phenols and alcohols. Triterpenoids are metabolites of isopentenyl pyrophosphate oligomers that




**Figure 3.** L-acetate fraction of Saudi propolis induced cell cycle arrest at G<sub>2</sub>M-phase in Jurkat cells. (A) Control cells, (B) Treated cells (100 µg/ml, 24 hours).



**Figure 4.** Induction of apoptosis in Jurkat cells after treatment the cells with L-acetate fraction of saudi propolis. After incubation times cells were stained with annexinV-FITC and PI and analysed with flow cytometry. (A) control (mehanol), (B) treated (100 µg/ml, 3 h), (C) treated, (100 µg/ml, 24 h), and (D) treated (100 µg/ml, 24 h).

are distributed throughout the plant kingdom<sup>85</sup>. The importance of triterpenoids as a source of medication for treating various chronic diseases is growing rapidly<sup>86</sup>. Many data suggest that both natural<sup>87,88</sup> as well as synthetic triterpenoids<sup>89,90</sup> have potential anticancer activities, and they act primarily by suppressing chronic inflammation by modulating pro-inflammatory mediators<sup>86</sup>. For example,  $\alpha$ - and  $\beta$ -amyirin acetates that were isolated from *Alstonia boonei* are known to inhibit inflammation in animal models<sup>91</sup>. However, we could not find a direct or indirect relationship in the literature between these compounds and the anti-tubulin activity detected in this study.

Many di- and triterpenoid phenols and alcohols with known biological activities have also been detected in the L-acetate fraction. The most abundant diterpenoid phenol was ferruginol, with a relative abundance of 4.9%. Knowledge of its anti-tumor activity has already been published<sup>92</sup>. Additionally, ferruginol is known to induce apoptosis in a caspase-dependent manner in non-small lung cancer cells<sup>93</sup>. The second-most abundant diterpenoid phenol in the L-acetate fraction was sugiol, with a relative abundance of 1.3%. In addition to its anti-inflammatory<sup>94</sup> and anticancer activities<sup>95</sup>, sugiol also exhibits antiviral activity against the H1N1 influenza



**Figure 5.** Representative photomicrograph of the histopathological examinations of both kidney and liver. (A,B) Control and treated renal tissues stained with Masson Trichrome (X 400). (C,D) Control and treated hepatic tissues stained with Masson Trichrome (X 400). (E,F) Control and treated hepatic tissues stained with Reticulin (X 400).

|                         | Control group    | Treated group     |
|-------------------------|------------------|-------------------|
| ALT (U/L)               | 236 ( $\pm$ 8.4) | 271 ( $\pm$ 12)   |
| AST (U/L)               | 52 ( $\pm$ 1.9)  | 64 ( $\pm$ 2.3)   |
| Cholesterol (mg/Dl)     | 55 ( $\pm$ 2.8)  | 67 ( $\pm$ 2.6)   |
| HDL-Cholesterol (mg/Dl) | 40 ( $\pm$ 1.4)  | 35 ( $\pm$ 2)     |
| Creatinine (mg/Dl)      | 2.1 ( $\pm$ 0.6) | 2.2 ( $\pm$ 0.7)  |
| Protein (g/100 ml)      | 6.5 ( $\pm$ 0.2) | 6.1 ( $\pm$ 0.15) |
| Glucose (mg/Dl)         | 131 ( $\pm$ 5.8) | 125 ( $\pm$ 6.2)  |

**Table 2.** Serum concentrations of AST, ALT, cholesterol, HDL, protein, creatinine and glucose in control and treated rats.

| Compound                        | Composition                                    | MW  | Relative Concentration (%) |
|---------------------------------|--|-----|----------------------------|
| Totarol                         | C <sub>20</sub> H <sub>30</sub> O              | 286 | 1.0                        |
| Ferruginol                      | C <sub>20</sub> H <sub>30</sub> O              | 286 | 4.9                        |
| Methyl octadecenoate            | C <sub>19</sub> H <sub>36</sub>                | 296 | 0.07                       |
| Hinokione                       | C <sub>20</sub> H <sub>28</sub> O <sub>2</sub> | 300 | 0.4                        |
| Sugiol                          | C <sub>20</sub> H <sub>28</sub> O <sub>2</sub> | 300 | 1.3                        |
| Hinokiol                        | C <sub>20</sub> H <sub>30</sub> O <sub>2</sub> | 302 | 0.31                       |
| Hydroginkgol                    | C <sub>21</sub> H <sub>36</sub> O              | 304 | 0.84                       |
| Squalene                        | C <sub>30</sub> H <sub>50</sub>                | 410 | 0.7                        |
| Urs-9(11), 12 dien-3-one        | C <sub>30</sub> H <sub>46</sub> O              | 422 | 1.3                        |
| Dammaradienol                   | C <sub>30</sub> H <sub>50</sub> O              | 426 | 1.07                       |
| Taraxasterol                    | C <sub>30</sub> H <sub>50</sub> O              | 426 | 1.4                        |
| Lup-20(29)en-3-one              | C <sub>30</sub> H <sub>48</sub> O              | 424 | 8.1                        |
| α-amyrin                        | C <sub>30</sub> H <sub>48</sub> O              | 424 | 4.8                        |
| Lanosterol                      | C <sub>30</sub> H <sub>50</sub> O              | 426 | 2.8                        |
| β-amyrone                       | C <sub>30</sub> H <sub>50</sub> O              | 426 | 5.1                        |
| β-amyrin                        | C <sub>30</sub> H <sub>48</sub> O              | 424 | 3.9                        |
| Cycloartenol                    | C <sub>30</sub> H <sub>50</sub> O              | 426 | 3.2                        |
| Moretenol                       | C <sub>30</sub> H <sub>50</sub> O              | 426 | 1.1                        |
| Lupeol                          | C <sub>30</sub> H <sub>50</sub> O              | 426 | 1.9                        |
| Olean-13(18)-en-3-one           | C <sub>30</sub> H <sub>50</sub> O <sub>2</sub> | 426 | 0.25                       |
| Hentriacontene                  | C <sub>31</sub> H <sub>62</sub>                | 434 | 0.67                       |
| Tritriacontene                  | C <sub>33</sub> H <sub>68</sub>                | 462 | 0.89                       |
| Oleana-9(11)-dien-3β-yl acetate | C <sub>32</sub> H <sub>50</sub> O <sub>2</sub> | 466 | 2.4                        |
| β-amyryl acetate                | C <sub>32</sub> H <sub>52</sub> O <sub>2</sub> | 468 | 11                         |
| Cycloartenyl acetate            | C <sub>32</sub> H <sub>52</sub> O <sub>2</sub> | 468 | 1.1                        |
| Lanostenyl acetate              | C <sub>32</sub> H <sub>52</sub> O <sub>2</sub> | 468 | 1.3                        |
| α-amyryl acetate                | C <sub>32</sub> H <sub>52</sub> O <sub>2</sub> | 468 | 18.2                       |
| β-lupenyl acetate               | C <sub>32</sub> H <sub>52</sub> O <sub>2</sub> | 468 | 2.8                        |
| α-lupenyl acetate               | C <sub>32</sub> H <sub>52</sub> O <sub>2</sub> | 468 | 12.1                       |
| Di-octyl-phthalate              | C <sub>24</sub> H <sub>38</sub> O <sub>4</sub> | 390 | 0.6                        |
| <b>Total</b>                    |  |     | <b>95.5</b>                |

**Table 3. Relative concentrations (%) of the major compounds in the L-acetate fraction of propolis from the Al-Baha region in Saudi Arabia.**


virus *in vitro*<sup>96</sup>. The last detected diterpenoid phenol was totarol, with a relative abundance of 1% of the total fraction. Totarol is known to inhibit the growth of several gram-positive bacteria. Jaiswal *et al.*<sup>97</sup> reported that totarol inhibits bacterial cytokinesis by interfering with the assembly and dynamics of Ftsz protein (a bacterial tubulin homolog)<sup>97,98</sup>. However, these researchers could not detect any effect on the HeLa cell microtubules<sup>97</sup>. Therefore, the anti-tubulin activity that has been detected in the L-acetate fraction seems to be induced via other components of the fraction and not from totarol. More recently, it has also been reported that totarol inhibits the secretion of some important *Staphylococcus aureus* virulence factors, namely the exotoxins alpha-hemolysin, staphylococcal enterotoxin A (SEA) and staphylococcal enterotoxin B (SEB)<sup>99</sup>. We also detected lupeol, a triterpenoid alcohol with antiangiogenic<sup>100</sup> and anti-inflammatory<sup>101</sup> activities. In addition to taraxasterol (1.4% abundance), a triterpenoid alcohol with anti-inflammatory and anti-arthritic activities was also found<sup>102</sup>.

All this information (when also considering the results of *in vivo* experiments) reflects the importance of Saudi propolis as a physiologically safe source of drug candidates with promising potential.

## Methods

**Propolis and metabolite extraction.** The Al-Baha region of Saudi Arabia, which is located in the southern part of the country, was chosen as the location from which propolis was collected from stationed hives. The total area of the patio is 10,362 square km, and it is located in the southwestern part of Saudi Arabia (coordinates 41° 27'E/20° 0'N) with an altitude range from 1550 to 1900 meters, including mountainous areas up to 2215 m. The local bee colonies were classified as *Apis mellifera jemenitica*. The propolis sample was collected using a stainless-steel spatula and saved in Teflon-capped glass containers, which were labeled properly and stored in a freezer until the analysis and biological studies.

**Methanol crude extraction.** Propolis (30 g) was extracted in methanol (300 ml, 95% v/v) by shaking the mixture at 150 rpm for 24 h at room temperature, and the suspension was then filtered. The residual propolis solid was further re-extracted and filtered in the same amount of methanol. The two extracts were pooled and kept



**Figure 6.** GC-MS analysis of L-Acetate fraction. (A) Total ion current (TIC) traces showing the major organic compounds. (B) Examples of typical GC-MS key ion plots ( $m/z$  189/218) for triterpenoids (U = unknown).

at  $-20^{\circ}\text{C}$  for 24 h to precipitate the wax and resin. The mixture was then centrifuged and evaporated in a rotary evaporator ( $40^{\circ}\text{C}$ ). The resulting residue (crude methanol extract) was weighed and dissolved in HPLC-grade methanol (Sigma Aldrich- Germany) at a final concentration of 10 mg/ml and stored at  $-20^{\circ}\text{C}$  until use.

**Column chromatography.** Two grams of silica gel was packed into a glass column. Ten ml of crude methanol extract was then mixed with silica gel, evaporated to dryness and loaded on top of the silica gel-containing column. The column was then eluted with ethyl acetate (500 ml) followed by methanol (500 ml). Pressure was applied to speed the flow rate of the solvent through the column, and two fractions were collected. Each fraction was solvent-evaporated in a rotary evaporator ( $40^{\circ}\text{C}$ ), and the residue was stored at  $-20^{\circ}\text{C}$ .

**Chemical Analysis.** Chemical analysis by gas chromatography-mass spectrometry (GC-MS) was performed with a Hewlett-Packard 6890 gas chromatograph coupled to a 5973 Mass Selective Detector, using a DB-5MS (Agilent)-fused silica capillary column ( $30\text{ m} \times 0.25\text{ mm i.d.}$ ,  $0.25\text{ }\mu\text{m}$  film thickness) with helium as the carrier gas. The GC temperature was programmed to ramp from  $65^{\circ}\text{C}$  (2 min initial hold) to  $310^{\circ}\text{C}$  at  $6^{\circ}\text{C min}^{-1}$  (it was isothermal for a 20-min final time), and the MS was operated in the electron impact mode at  $70\text{ eV}$  of ion source energy. Mass spectrometric data were acquired and processed using the GC-MS ChemStation data system. The retention times were compared with those of the external standards. The compounds were identified by comparing them with the chromatographic retention characteristics and mass spectra of authentic standards, and the mass spectra and the mass spectral library of the GC-MS data system were reported. The mass spectra of unknown compounds were interpreted on the basis of their fragmentation patterns. The identification of triterpenoids, n-alkenes, n-alkanes and methyl n-alkanoates are based primarily on their mass spectra (i.e., the key ions at  $m/z$  values of 191/189/218, 97, 85, and 87, respectively). The compounds were quantified using the total ion current (TIC) peak area. A procedural blank was run in sequence with the propolis sample, and it presented no significant background interference.

**Cell proliferation assay.** The growth inhibition was measured in a 96-well plate. Aliquots of  $120\text{ }\mu\text{l}$  of the suspended cells ( $10^5\text{ ml}^{-1}$ ) were added to  $60\text{ }\mu\text{l}$  of serially diluted extracts in the cultivation media. After 4 days of incubation, the growth was determined by MTT assay as described previously<sup>103</sup>.

**Impedance Profiling.** Impedance measurements of the treated and control cells were performed on an RT-CES system (xCELLigence) from Acea Biosciences (Roche) as described previously<sup>104</sup>. In brief, for the time-dependent cell response profiling,  $60\text{ }\mu\text{l}$  of Dulbecco's modified Eagle's medium (DMEM) was added to 96-well E-Plates to obtain background readings, followed by the addition of  $120\text{ }\mu\text{l}$  of L-929 cell suspension. The stock solution of the L-acetate fraction in DMSO was diluted with the cultivation medium to obtain a final test concentration for the  $\text{IC}_{90}$  of less than 0.1% DMSO. One  $\mu\text{l}$  of each prepared solution was then transferred into the 96-well E-Plate. Each E-plate also contained DMSO-only wells as the solvent control. The reference compounds



and the ethyl acetate fraction with an unknown mode of action were measured in triplicate, and they were randomly distributed over the microtiter plates to avoid batch effects. The measurements were run for 5 days.

In using hierarchical cluster analysis and co-clustering, we compared the action of the reference compounds with a known mechanism of action to that of the L-acetate fraction to identify its mechanism of action.

**Cell cycle analysis.** As described previously<sup>105</sup>, Jurkat cells were treated with different concentrations of the L-acetate fraction (or methanol (-ve control)) for 24 and 48 hours and then harvested by centrifugation. The cells were then fixed in methanol (80%) at  $-20^{\circ}\text{C}$  for 30 min, washed with PBS, and then treated with saponin (0.1% w/v) in PBS. Finally, the cells were treated with RNase, and the nuclei were stained with propidium iodide ( $20\text{ mg mL}^{-1}$ ) for 30 min at  $37^{\circ}\text{C}$ . The DNA content was measured with a FACSCalibur instrument (Becton Dickinson); 30,000 events were collected for each experiment. The data were analyzed with CellQuest software (Becton Dickinson).

**Microtubule staining.** As described previously<sup>105</sup>, PtK<sub>2</sub> cells were grown on glass cover slips in four-well plates. Exponentially growing cells were incubated with different concentrations of the extract for different time periods. The supernatant was removed and the cells were fixed in a  $-20^{\circ}\text{C}$  mixture of acetone/methanol (1 + 1) for 10 min. The fixed cells were washed twice with PBS and treated with anti- $\alpha$ -tubulin antibody (1:500 dilution, Sigma) for 45 min at  $37^{\circ}\text{C}$ . The cells were then washed again with PBS and treated with anti-mouse-Alexa Flour 594 (1:10<sup>4</sup> dilution, Molecular Probes). The nuclei were stained with DAPI (4-6-diamidino-2-phenylindole) solution ( $0.1\text{ mg mL}^{-1}$ ) in PBS for 3 min. The cells were then examined with a fluorescence microscope equipped with the appropriate filters (Zeiss-Germany).

**Experimental animals.** Male rats (*Rattus norvegicus*) were obtained from the college of pharmacy at King Saud University. The weight of each rat ranged from 150 to 170 grams. The animals were maintained at  $18\text{--}22^{\circ}\text{C}$  in polypropylene cages and exposed to 12:12 h light:dark cycles. Before the experiment was started, the rats were allowed to acclimate to the laboratory environment for seven days. The study protocol was approved by the Animal Ethics Committee of the Zoology Department in the College of Science at King Saud University. For the experiment, the rats were divided into two groups ( $n = 10$ ), namely a control group (receiving the vehicle) and a treated group (receiving a daily intra-peritoneal dose of 1 mg/kg body weight of the L-acetate fraction for ten days).

**Blood, kidney and liver samples.** The animals were autopsied under light ether anesthesia. The blood needed for the experiment was obtained from the retro-orbital venous sinus. The liver enzymes, total protein and lipid profiles were estimated from the separated plasma. The kidney and liver were washed in cold saline and processed for histological studies.

**Liver function tests and lipid profile.** The concentrations of liver enzymes, HDL, cholesterol, protein, creatinine and glucose in the serum were estimated according to the manufacturer's protocols (Bio Merieux kits, France). A UV/Visible-Model-80-2106-00 spectrophotometer (Pharmacia Biotech, Cambridge, England) was used to determine the colorimetric responses of the proteins.

**Histological study.** The kidney and liver tissue sections were processed using light microscopy. The sections were fixed in 10% neutral formalin, embedded in paraffin and then stained with hematoxylin-eosin, Masson trichrome and reticulin stains. The tissue damage was investigated in a blind fashion using a DMRB/E light microscope (Leica, Heerbrugg, Switzerland).

**Statistical analysis.** MINITAB software (MINITAB, State College, PA, Version 13.1, 2002) was used to analyze the data. The data were tested for normality (with the Anderson Darling test and for variance homogeneity) prior to any further statistical analysis. The normally distributed data with homogeneous variances were analyzed using a one-way ANOVA. The results were expressed as the means (M)  $\pm$  standard deviation (SD).

**Ethical Clearance.** All animal procedures were conducted in accordance with the standards set forth in the guidelines for the care and use of experimental animals by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and the National Institutes of Health (NIH). The study protocol was approved by the Animal Ethics Committee of the Zoology Department in the College of Science at King Saud University, KSA.

## Conclusions

The L-acetate bio-active fraction of Saudi propolis that was isolated from the Al-Bahah region has been characterized using GC-MS techniques. The major compounds were triterpenoids and diterpenoids. The predominant triterpenoids were  $\alpha$ - and  $\beta$ -amyrin acetates,  $\alpha$ - and  $\beta$ -amyrins, and  $\alpha$ - and  $\beta$ -lupeyl acetates, followed by lupeol, ferruginol, sugiol, taraxasterol and totarol. The fraction showed anti-tubulin activity combined with G<sub>2</sub>M cell cycle arrest and apoptotic induction in cancer cell lines. This study reinforces the need to understand the therapeutic potential of Saudi propolis.

## References

1. Torre, L. A. *et al.* Global cancer statistics, 2012. *CA: a cancer journal for clinicians* **65**, 87–108, doi: 10.3322/caac.21262 (2015).
2. Walker, F. E. Paclitaxel (TAXOL): side effects and patient education issues. *Seminars in oncology nursing* **9**, 6–10 (1993).
3. Uchida, J. *et al.* Comparison of side effects caused by intra-arterial and intravenous infusion of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for urothelial cancer. *Hinyokika kyo. Acta urologica Japonica* **43**, 637–640 (1997).

4. Brockmann, B., Geschke, E., Schmidt, U. M. & Ebeling, K. Therapeutic results and toxic side effects of the cytosatan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer. *Geburtshilfe und Frauenheilkunde* **51**, 383–386, doi: 10.1055/s-2007-1026163 (1991).
5. Brockmann, B., Kirchhof, I., Geschke, E. & Schmidt, U. M. Therapeutic results and toxic side effects of the combination cytosatan, adriamycin and vincristine as second-line therapy of metastatic breast cancer. *Archiv fur Geschwulstforschung* **59**, 341–346 (1989).
6. Leonardi, M. C. *et al.* Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electrons as sole treatment. *Tumori* **98**, 324–330, doi: 10.1700/1125.12400 (2012).
7. Solberg, A., Widmark, A., Tasdemir, I., Ahlgren, G. & Angelsen, A. Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial. *Scandinavian journal of urology and nephrology* **45**, 233–238, doi: 10.3109/00365599.2011.560577 (2011).
8. Au, W. Y., Hung, K. N., Wan, T. S. & Ma, E. Side effects related to cancer treatment: CASE 3. Primary cerebral lymphoma after radiotherapy for recurrent meningioma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* **23**, 8535–8536, doi: 10.1200/JCO.2004.00.6817 (2005).
9. Naka, N. & Kawahara, M. Side effects of radiotherapy in lung cancer and their treatment. *Nihon rinsho. Japanese journal of clinical medicine* **60** Suppl 5, 411–413 (2002).
10. Burdock, G. A. Review of the biological properties and toxicity of bee propolis (propolis). *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* **36**, 347–363 (1998).
11. Cherniack, E. P. Bugs as drugs, Part 1: Insects: the “new” alternative medicine for the 21st century? *Alternative medicine review: a journal of clinical therapeutic* **15**, 124–135 (2010).
12. Abd El Hady, F. K. & Hegazi, A. G. Egyptian propolis: 2. Chemical composition, antiviral and antimicrobial activities of East Nile Delta propolis. *Zeitschrift fur Naturforschung. C, Journal of biosciences* **57**, 386–394 (2002).
13. Acikelli, A. H. *et al.* Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines. *International journal of clinical pharmacology and therapeutics* **51**, 51–53 (2013).
14. Aghel, S. *et al.* Effect of Iranian Propolis on Salivary Total Antioxidant Capacity in Gamma-irradiated Rats. *Journal of dental research, dental clinics, dental prospects* **8**, 235–239, doi: 10.5681/joddd.2014.042 (2014).
15. Ali, F. H., Kassem, G. M. & Atta-Alla, O. A. Propolis as a natural decontaminant and antioxidant in fresh oriental sausage. *Veterinaria italiana* **46**, 167–172 (2010).
16. Alvareda, E. *et al.* 196 Antiinflammatory activity of phenolic compounds extracted from Uruguayan propolis and grape. *Journal of biomolecular structure & dynamics* **33** Suppl 1, 129, doi: 10.1080/07391102.2015.1032833 (2015).
17. Al-Waili, N., Al-Ghamdi, A., Ansari, M. J., Al-Attal, Y. & Salom, K. Synergistic effects of honey and propolis toward drug multi-resistant *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans* isolates in single and polymicrobial cultures. *International journal of medical sciences* **9**, 793–800, doi: 10.7150/ijms.4722 (2012).
18. Amoros, M. *et al.* Comparison of the anti-herpes simplex virus activities of propolis and 3-methyl-but-2-enyl caffeate. *Journal of natural products* **57**, 644–647 (1994).
19. Aso, K., Kanno, S., Tadano, T., Satoh, S. & Ishikawa, M. Inhibitory effect of propolis on the growth of human leukemia U937. *Biological & pharmaceutical bulletin* **27**, 727–730 (2004).
20. Bankova, V. *et al.* Antibacterial diterpenic acids from Brazilian propolis. *Zeitschrift fur Naturforschung. C, Journal of biosciences* **51**, 277–280 (1996).
21. Barud Hda, S. *et al.* Antimicrobial Brazilian Propolis (EPP-AF) Containing Biocellulose Membranes as Promising Biomaterial for Skin Wound Healing. *Evidence-based complementary and alternative medicine: eCAM* **2013**, 703024, doi: 10.1155/2013/703024 (2013).
22. Bazvand, L. *et al.* Antibacterial effect of triantibiotic mixture, chlorhexidine gel, and two natural materials Propolis and Aloe vera against *Enterococcus faecalis*: An *ex vivo* study. *Dental research journal* **11**, 469–474 (2014).
23. Bosio, K., Avanzini, C., D'Avolio, A., Ozino, O. & Savoia, D. *In vitro* activity of propolis against *Streptococcus pyogenes*. *Letters in applied microbiology* **31**, 174–177 (2000).
24. Brumfitt, W., Hamilton-Miller, J. M. & Franklin, I. Antibiotic activity of natural products: 1. Propolis. *Microbios* **62**, 19–22 (1990).
25. Omar, R. M. *et al.* Chemical characterisation of Nigerian red propolis and its biological activity against *Trypanosoma Brucei*. *Phytochemical analysis: PCA* **27**, 107–115, doi: 10.1002/pca.2605 (2016).
26. Cuesta-Rubio, O. *et al.* Chemical characterization of Cuban propolis by HPLC-PDA, HPLC-MS, and NMR: the brown, red, and yellow Cuban varieties of propolis. *Journal of agricultural and food chemistry* **55**, 7502–7509, doi: 10.1021/jf071296w (2007).
27. Sulaiman, G. M. *et al.* Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* **49**, 2415–2421, doi: 10.1016/j.fct.2011.06.060 (2011).
28. Frozza, C. O. *et al.* Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* **52**, 137–142, doi: 10.1016/j.fct.2012.11.013 (2013).
29. Bankova, V., Christov, R., Kujumgiev, A., Marcucci, M. C. & Popov, S. Chemical composition and antibacterial activity of Brazilian propolis. *Zeitschrift fur Naturforschung. C, Journal of biosciences* **50**, 167–172 (1995).
30. Bankova, V., Popova, M., Bogdanov, S. & Sabatini, A. G. Chemical composition of European propolis: expected and unexpected results. *Zeitschrift fur Naturforschung. C, Journal of biosciences* **57**, 530–533 (2002).
31. Johnson, K. S., Eischen, F. A. & Giannasi, D. E. Chemical composition of North American bee propolis and biological activity towards larvae of greater wax moth (Lepidoptera: Pyralidae). *Journal of chemical ecology* **20**, 1783–1791, doi: 10.1007/BF02059899 (1994).
32. Bankova, V., Galabov, A. S., Antonova, D., Vilhelmova, N. & Di Perri, B. Chemical composition of Propolis Extract ACF(R) and activity against herpes simplex virus. *Phytomedicine: international journal of phytotherapy and phytopharmacology* **21**, 1432–1438, doi: 10.1016/j.phymed.2014.04.026 (2014).
33. Christov, R., Trusheva, B., Popova, M., Bankova, V. & Bertrand, M. Chemical composition of propolis from Canada, its antiradical activity and plant origin. *Natural product research* **19**, 673–678, doi: 10.1080/14786410512331328159 (2005).
34. Chanyshv, Z. G. & Kudashev, A. K. Chemical composition of propolis. *Veterinariia*, **100** (1976).
35. Shinohara, R., Ohta, Y., Hayashi, T. & Ikono, T. Evaluation of antilipid peroxidative action of propolis ethanol extract. *Phytotherapy research: PTR* **16**, 340–347, doi: 10.1002/ptr.894 (2002).
36. Souza, R. M., de Souza, M. C., Patitucci, M. L. & Silva, J. F. Evaluation of antioxidant and antimicrobial activities and characterization of bioactive components of two Brazilian propolis samples using a pKa-guided fractionation. *Zeitschrift fur Naturforschung. C, Journal of biosciences* **62**, 801–807 (2007).
37. Barros, M. P. *et al.* Evaluation of antiulcer activity of the main phenolic acids found in Brazilian Green Propolis. *Journal of ethnopharmacology* **120**, 372–377, doi: 10.1016/j.jep.2008.09.015 (2008).
38. Shukla, S., Bhadauria, M. & Jadon, A. Evaluation of hepatoprotective potential of propolis extract in carbon tetrachloride induced liver injury in rats. *Indian journal of biochemistry & biophysics* **42**, 321–325 (2005).
39. Gunduz, C. *et al.* Evaluation of Manisa propolis effect on leukemia cell line by telomerase activity. *Leukemia research* **29**, 1343–1346, doi: 10.1016/j.leukres.2005.04.010 (2005).

40. Araujo, M. J. *et al.* Pharmacognostic and acute toxicological evaluation of *Scaptotrigona aff. postica* propolis extract in pre-clinical assays. *Natural product research* **25**, 1037–1046, doi: 10.1080/14786419.2010.482059 (2011).
41. Thomzner, J., Bekemeier, H., Schneidewind, E. M. & Wenzel, U. Pharmacokinetic studies of the propolis constituent pinocembrin in the rat (author's transl). *Die Pharmazie* **34**, 185–187 (1979).
42. Nirala, S. K. *et al.* Pharmacological intervention of tiferon and propolis to alleviate beryllium-induced hepatorenal toxicity. *Fundamental & clinical pharmacology* **22**, 403–415, doi: 10.1111/j.1472-8206.2008.00603.x (2008).
43. Freires, I. A., de Alencar, S. M. & Rosalen, P. L. A pharmacological perspective on the use of Brazilian Red Propolis and its isolated compounds against human diseases. *European journal of medicinal chemistry* **110**, 267–279, doi: 10.1016/j.ejmech.2016.01.033 (2016).
44. Bankova, V., Popova, M. & Trusheva, B. Propolis volatile compounds: chemical diversity and biological activity: a review. *Chemistry Central journal* **8**, 28, doi: 10.1186/1752-153X-8-28 (2014).
45. Thomson, W. M. Propolis. *The Medical journal of Australia* **153**, 654 (1990).
46. Kuropatnicki, A. K., Szliszka, E. & Krol, W. Historical aspects of propolis research in modern times. *Evidence-based complementary and alternative medicine:eCAM* **2013**, 964149, doi: 10.1155/2013/964149 (2013).
47. Jerz, G. *et al.* Preparative mass-spectrometry profiling of bioactive metabolites in Saudi-Arabian propolis fractionated by high-speed countercurrent chromatography and off-line atmospheric pressure chemical ionization mass-spectrometry injection. *Journal of chromatography. A* **1347**, 17–29, doi: 10.1016/j.chroma.2014.04.068 (2014).
48. Shaheen, S. A., Zarga, M. H., Nazer, I. K., Darwish, R. M. & Al-Jaber, H. I. Chemical constituents of Jordanian propolis. *Natural product research* **25**, 1312–1318, doi: 10.1080/14786419.2010.509060 (2011).
49. Athikomkulchai, S., Awale, S., Ruangrunsi, N., Ruchirawat, S. & Kadota, S. Chemical constituents of Thai propolis. *Fitoterapia* **88**, 96–100, doi: 10.1016/j.fitote.2013.04.008 (2013).
50. Bankova, V. Chemical diversity of propolis and the problem of standardization. *Journal of ethnopharmacology* **100**, 114–117, doi: 10.1016/j.jep.2005.05.004 (2005).
51. Nina, N. *et al.* Chemical profiling and antioxidant activity of Bolivian propolis. *Journal of the science of food and agriculture* **96**, 2142–2153, doi: 10.1002/jsfa.7330 (2016).
52. Mavri, A. *et al.* Chemical properties and antioxidant and antimicrobial activities of Slovenian propolis. *Chemistry & biodiversity* **9**, 1545–1558, doi: 10.1002/cbdv.201100337 (2012).
53. de Groot, A. Chemicals found in poplar-type propolis. *Dermatitis : contact, atopic, occupational, drug* **25**, 280, doi: 10.1097/DER.000000000000069 (2014).
54. Tyagi, S. P. *et al.* Comparison of antimicrobial efficacy of propolis, *Morinda citrifolia*, *Azadirachta indica* (Neem) and 5% sodium hypochlorite on *Candida albicans* biofilm formed on tooth substrate: An *in-vitro* study. *Journal of conservative dentistry: JCD* **16**, 532–535, doi: 10.4103/0972-0707.120973 (2013).
55. Al-Haj Ali, S. N., Al-Jundi, S. & Mhaidat, N. Comparison of Coconut Water and Jordanian Propolis on Survival of Bench-dried Periodontal Ligament Cells: An *in vitro* Cell Culture Study. *International journal of clinical pediatric dentistry* **6**, 161–165, doi: 10.5005/jp-journals-10005-1211 (2013).
56. Janes, K. & Bumba, V. Composition of bee glue (propolis). *Die Pharmazie* **29**, 544–545 (1974).
57. Inouye, S., Takahashi, M. & Abe, S. Composition, antifungal and radical scavenging activities of 4 propolis. *Medical mycology journal* **52**, 305–313 (2011).
58. Awale, S. *et al.* Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. *Bioorganic & medicinal chemistry* **16**, 181–189, doi: 10.1016/j.bmc.2007.10.004 (2008).
59. Usia, T. *et al.* Constituents of Chinese propolis and their antiproliferative activities. *Journal of natural products* **65**, 673–676 (2002).
60. Kurek-Gorecka, A. M. *et al.* Antioxidant activity of ethanolic fractions of Polish propolis. *Zeitschrift fur Naturforschung. C, Journal of biosciences* **67**, 545–550 (2012).
61. Popova, M. *et al.* Antioxidant and alpha-Glucosidase Inhibitory Properties and Chemical Profiles of Moroccan Propolis. *Natural product communications* **10**, 1961–1964 (2015).
62. Yang, H. *et al.* Antioxidant compounds from propolis collected in Anhui, China. *Molecules* **16**, 3444–3455, doi: 10.3390/molecules16043444 (2011).
63. Kumazawa, S. *et al.* Antioxidant prenylated flavonoids from propolis collected in Okinawa, Japan. *Journal of agricultural and food chemistry* **55**, 7722–7725, doi: 10.1021/jf071187h (2007).
64. Moreira, L., Dias, L. G., Pereira, J. A. & Estevinho, L. Antioxidant properties, total phenols and pollen analysis of propolis samples from Portugal. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* **46**, 3482–3485, doi: 10.1016/j.fct.2008.08.025 (2008).
65. Katalinic, V., Radic, S., Ropac, D., Mulic, R. & Katalinic, A. [Antioxidative activity of propolis from Dalmatia (Croatia)]. *Acta medica Croatica: casopis Hrvatske akademije medicinskih znanosti* **58**, 373–376 (2004).
66. Shimizu, K., Ashida, H., Matsuura, Y. & Kanazawa, K. Antioxidative bioavailability of artemillin C in Brazilian propolis. *Archives of biochemistry and biophysics* **424**, 181–188, doi: 10.1016/j.abb.2004.02.021 (2004).
67. Li, H. *et al.* Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin. *International journal of oncology* **31**, 601–606 (2007).
68. Pratsinis, H., Kletsas, D., Melliou, E. & Chinou, I. Antiproliferative activity of Greek propolis. *Journal of medicinal food* **13**, 286–290, doi: 10.1089/jmf.2009.0071 (2010).
69. Catchpole, O., Mitchell, K., Bloor, S., Davis, P. & Suddes, A. Antiproliferative activity of New Zealand propolis and phenolic compounds vs human colorectal adenocarcinoma cells. *Fitoterapia* **106**, 167–174, doi: 10.1016/j.fitote.2015.09.004 (2015).
70. Banskota, A. H. *et al.* Antiproliferative activity of the Netherlands propolis and its active principles in cancer cell lines. *Journal of ethnopharmacology* **80**, 67–73 (2002).
71. Demir, S. *et al.* Antiproliferative and proapoptotic activity of Turkish propolis on human lung cancer cell line. *Nutrition and cancer* **68**, 165–172, doi: 10.1080/01635581.2016.1115096 (2016).
72. Massaro, C. F. *et al.* Anti-staphylococcal activity of C-methyl flavanones from propolis of Australian stingless bees (*Tetragonula carbonaria*) and fruit resins of *Corymbia torelliana* (Myrtaceae). *Fitoterapia* **95**, 247–257, doi: 10.1016/j.fitote.2014.03.024 (2014).
73. da Silva Cunha, I. B. *et al.* Antitrypanosomal activity of Brazilian propolis from *Apis mellifera*. *Chemical & pharmaceutical bulletin* **52**, 602–604 (2004).
74. Wang, B. J. & Zhang, H. J. Studies on the chemical constituents of Beijing propolis. *Zhong yao tong bao* **13**, 37–38, 63 (1988).
75. Mahmoud, A. S., Almas, K. & Dahlan, A. A. The effect of propolis on dentinal hypersensitivity and level of satisfaction among patients from a university hospital Riyadh, Saudi Arabia. *Indian journal of dental research: official publication of Indian Society for Dental Research* **10**, 130–137 (1999).
76. al-Said, M. S. Traditional medicinal plants of Saudi Arabia. *The American journal of Chinese medicine* **21**, 291–298, doi: 10.1142/S0192415X93000340 (1993).
77. Yildirim, A. *et al.* Antiviral Activity of Hatay Propolis Against Replication of Herpes Simplex Virus Type 1 and Type 2. *Medical science monitor: international medical journal of experimental and clinical research* **22**, 422–430 (2016).
78. Veloz, J. J. *et al.* Antibiofilm Activity of Chilean Propolis on *Streptococcus mutans* Is Influenced by the Year of Collection. *BioMed research international* **2015**, 291351, doi: 10.1155/2015/291351 (2015).

79. Suleman, T., van Vuuren, S., Sandasi, M. & Viljoen, A. M. Antimicrobial activity and chemometric modelling of South African propolis. *Journal of applied microbiology* **119**, 981–990, doi: 10.1111/jam.12906 (2015).
80. Nina, N. *et al.* Antibacterial Activity, Antioxidant Effect and Chemical Composition of Propolis from the Region del Maule, Central Chile. *Molecules* **20**, 18144–18167, doi: 10.3390/molecules201018144 (2015).
81. Valenzuela-Barra, G. *et al.* Anti-inflammatory activity and phenolic profile of propolis from two locations in Region Metropolitana de Santiago, Chile. *Journal of ethnopharmacology* **168**, 37–44, doi: 10.1016/j.jep.2015.03.050 (2015).
82. de Aguiar, S. C. *et al.* Antimicrobial activity of Brazilian propolis extracts against rumen bacteria *in vitro*. *World journal of microbiology & biotechnology* **29**, 1951–1959, doi: 10.1007/s11274-013-1361-x (2013).
83. Potkonjak, N. I. *et al.* Antioxidant activity of propolis extracts from Serbia: a polarographic approach. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* **50**, 3614–3618, doi: 10.1016/j.fct.2012.07.029 (2012).
84. Choudhari, M. K., Punekar, S. A., Ranade, R. V. & Paknikar, K. M. Antimicrobial activity of stingless bee (*Trigona* sp.) propolis used in the folk medicine of Western Maharashtra, India. *Journal of ethnopharmacology* **141**, 363–367, doi: 10.1016/j.jep.2012.02.047 (2012).
85. Zhang, X. *et al.* Triterpenoids from the roots of *Rubus parvifolius*. *Chin J Nat Med* **14**, 377–381, doi: 10.3724/SPJ.1009.2016.00377 (2016).
86. Patlolla, J. M. & Rao, C. V. Triterpenoids for cancer prevention and treatment: current status and future prospects. *Curr Pharm Biotechnol* **13**, 147–155 (2012).
87. Liu, J., Wang, Y., Liu, R. H. & He, X. Novel triterpenoids isolated from raisins exert potent antiproliferative activities by targeting mitochondrial and Ras/Raf/ERK signaling in human breast cancer cells. *Food Funct* **7**, 3244–3251, doi: 10.1039/c6fo00768f (2016).
88. Pettit, G. R. *et al.* Isolation and Structure of Cancer Cell Growth Inhibitory Tetracyclic Triterpenoids from the Zimbabwean *Monadenium lugardae*. *Journal of natural products* **79**, 1598–1603, doi: 10.1021/acs.jnatprod.6b00107 (2016).
89. Hyer, M. L. *et al.* Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. *Cancer Res* **65**, 4799–4808, doi: 10.1158/0008-5472.CAN-04-3319 (2005).
90. Liby, K. T. Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. *Dose Response* **12**, 136–151, doi: 10.2203/dose-response.13-018.Liby (2014).
91. Okoye, N. N. *et al.* beta-Amyrin and alpha-amyrin acetate isolated from the stem bark of *Alstonia boonei* display profound anti-inflammatory activity. *Pharm Biol* **52**, 1478–1486, doi: 10.3109/13880209.2014.898078 (2014).
92. Bispo de Jesus, M. *et al.* Ferruginol suppresses survival signaling pathways in androgen-independent human prostate cancer cells. *Biochimie* **90**, 843–854, doi: 10.1016/j.biochi.2008.01.011 (2008).
93. Ho, S. T., Tung, Y. T., Kuo, Y. H., Lin, C. C. & Wu, J. H. Ferruginol inhibits non-small cell lung cancer growth by inducing caspase-associated apoptosis. *Integr Cancer Ther* **14**, 86–97, doi: 10.1177/1534735414555806 (2015).
94. Chao, K. P., Hua, K. F., Hsu, H. Y., Su, Y. C. & Chang, S. T. Anti-inflammatory activity of sugiol, a diterpene isolated from *Calocedrus formosana* bark. *Planta Med* **71**, 300–305, doi: 10.1055/s-2005-864094 (2005).
95. Jung, S. N. *et al.* Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells. *Biochem Pharmacol* **97**, 38–50, doi: 10.1016/j.bcp.2015.06.033 (2015).
96. Bajpai, V. K., Kim, N. H., Kim, K. & Kang, S. C. Antiviral potential of a diterpenoid compound sugiol from *Metasequoia glyptostroboides*. *Pak J Pharm Sci.* **29**, 1077–80 (2016).
97. Jaiswal, R., Beuria, T. K., Mohan, R., Mahajan, S. K. & Panda, D. Totarol inhibits bacterial cytokinesis by perturbing the assembly dynamics of FtsZ. *Biochemistry* **46**, 4211–4220, doi: 10.1021/bi602573e (2007).
98. Dyer, N. Tubulin and its prokaryotic homologue FtsZ: a structural and functional comparison. *Sci Prog* **92**, 113–137 (2009).
99. Shi, C. *et al.* Inhibitory effect of totarol on exotoxin proteins hemolysin and enterotoxins secreted by *Staphylococcus aureus*. *World journal of microbiology & biotechnology* **31**, 1565–1573, doi: 10.1007/s11274-015-1905-3 (2015).
100. You, Y. J., Nam, N. H., Kim, Y., Bae, K. H. & Ahn, B. Z. Antiangiogenic activity of lupeol from *Bombax ceiba*. *Phytotherapy research: PTR* **17**, 341–344, doi: 10.1002/ptr.1140 (2003).
101. Geetha, T. & Varalakshmi, P. Anti-inflammatory activity of lupeol and lupeol linoleate in rats. *Journal of ethnopharmacology* **76**, 77–80 (2001).
102. Wang, S. *et al.* Anti-inflammatory and anti-arthritic effects of taraxasterol on adjuvant-induced arthritis in rats. *Journal of ethnopharmacology* **187**, 42–48, doi: 10.1016/j.jep.2016.04.031 (2016).
103. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* **65**, 55–63 (1983).
104. Schneider, T. *et al.* Deciphering intracellular targets of organochalcogen based redox catalysts. *Med. Chem. Commun.* **3**, 784–787, doi: 10.1039/C2MD20049J (2012).
105. Elnakady, Y. A., Sasse, F., Lunsdorf, H. & Reichenbach, H. Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. *Biochem Pharmacol* **67**, 927–935 (2004).

## Acknowledgements

This project was funded by the National Plan for Science, Technology, and Innovation (MAARIFAH), King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, Award Number (10-BIO 1173-02).

## Author Contributions

A.I.R. conducted the GC-MS analysis. R.F. conducted the hierarchical analysis. H.E. performed the data collection. N.A. conducted the material analysis. M.B. provided technical support with the measurements. A.A.G. collected and managed the propolis production. M.O.M.O. managed the bee hives. Y.A.E. conceived the idea, performed cell studies, supervised experiments, analyzed the data and wrote the manuscript. All the authors read and corrected the manuscript.

## Additional Information

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Elnakady, Y. A. *et al.* Characteristics, chemical compositions and biological activities of propolis from Al-Bahah, Saudi Arabia. *Sci. Rep.* **7**, 41453; doi: 10.1038/srep41453 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017